June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Optical coherence tomography for screening of orthotopic retinoblastoma xenografts
Author Affiliations & Notes
  • Andrea Wenzel
    Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
  • Brian Samuels
    Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
  • Timothy Corson
    Ophthalmology, Indiana University School of Medicine, Indianapolis, IN
    Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN
  • Footnotes
    Commercial Relationships Andrea Wenzel, None; Brian Samuels, Merck & Co., Inc (F), Merck & Co., Inc (C), ICHE (C); Timothy Corson, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3967. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrea Wenzel, Brian Samuels, Timothy Corson; Optical coherence tomography for screening of orthotopic retinoblastoma xenografts. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3967.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Retinoblastoma is the most common intraocular tumor in children, often causing blindness. Orthotopic xenograft models are a critical tool for studying new therapeutic methods. A successful xenograft model has been generated by intravitreal injection of newborn rats with a bioluminescent derivative of the Y79 human retinoblastoma cell line. Although this model is powerful, screening panels of xenografts from multiple cell lines would be valuable for assessing inter-individual responses to novel therapeutics. We evaluated whether optical coherence tomography (OCT) could be used to identify successful xenografts of other, non-engineered retinoblastoma cell lines and characterize xenograft growth patterns.

Methods: Sprague-Dawley rats (P0) received an intravitreal injection of 1,000 to 250,000 retinoblastoma cells from either the standard bioluminescent/EGFP+ Y79 cell line or other, non-engineered retinoblastoma cell lines. The Micron III rodent imaging system was used to obtain fundus photographs and OCT images regularly over the course of 4 weeks to document xenograft development.

Results: Using in vivo, intraocular, EGFP fluorescence imaging as a guide, previously described Y79-EGFP-luciferase xenografts were characterized by OCT. The xenografts produced both small and large tumors that were typically dense, highly vascularized, and had well-defined edges. While direct retinal involvement was rare, xenografts appeared to preferentially grow just posterior to the lens suggesting that the regressing tunica vasculosa lentis and/or the regressing hyaloid artery may be the preferred vascular source. Successful non-fluorescent xenografts had similar morphologic characteristics and growth patterns to those from the Y79 line on OCT imaging.

Conclusions: OCT imaging of retinoblastoma orthotopic xenografts is a novel way to spatially analyze and follow tumor growth in vivo. When tumors were not always readily evident on brightfield imaging, OCT proved to be a valuable tool to help identify hard-to-see, non-fluorescent tumors generated with these non-engineered retinoblastoma cell lines. This approach will enable rapid screening of additional cell lines in the future as well as quantitative spatial analysis of response to therapeutics.

Keywords: 703 retinoblastoma • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 551 imaging/image analysis: non-clinical  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.